MiR-185-5p suppresses acute myeloid leukemia by inhibiting GPX1

Bo Pang1, Hanwen Mao2, Jing Wang3

  • 1Department of Geriatrics, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan 430015, Hubei, China.

Microvascular Research
|December 5, 2021
PubMed

Insights

This study reveals that microRNA-185-5p (miR-185-5p) inhibits acute myeloid leukemia (AML) progression by targeting GPX1. Upregulating miR-185-5p restricts AML cell growth and promotes differentiation.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Acute myeloid leukemia (AML) is a rapidly progressing blood cancer.
  • Understanding molecular mechanisms driving AML is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of the miR-185-5p-GPX1 axis in acute myeloid leukemia (AML) progression and differentiation.
  • To elucidate the functional impact of miR-185-5p and GPX1 on AML cell behavior.

Main Methods:

  • Quantitative real-time PCR was used to assess miR-185-5p and GPX1 expression levels in AML.
  • Functional assays were performed to evaluate the effects of miR-185-5p upregulation and GPX1 overexpression on AML cell proliferation, invasion, differentiation, and apoptosis.

Main Results:

  • miR-185-5p levels were significantly decreased, while GPX1 levels were elevated in AML.
  • Upregulation of miR-185-5p suppressed AML cell proliferation and invasion, while promoting differentiation and apoptosis.
  • Overexpression of GPX1 enhanced AML cell growth.

Conclusions:

  • The miR-185-5p-GPX1 axis plays a critical role in regulating AML progression.
  • miR-185-5p inhibits AML by targeting and downregulating GPX1, thereby reducing cell proliferation and invasion.